A Randomized, Double-Blind,
Placebo-Controlled, Dose-Ranging Trial
of Tafenoquine for Weekly Prophylaxis
against \u3ci\u3ePlasmodium falciparum\u3c/i\u3e by Hale, Braden R. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
U.S. Navy Research U.S. Department of Defense 
2003 
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging 
Trial of Tafenoquine for Weekly Prophylaxis against Plasmodium 
falciparum 
Braden R. Hale 
U.S. Navy Medical Research Unit # 3 
Seth Owusu-Agyei 
Navrongo Health Research Center 
David J. Fryauff 
Naval Medical Research Center, fryauffd@nmrc.navy.mil 
Kwadwo A. Koram 
Noguchi Memorial Institute of Medical Research 
Martin Adjuik 
Navrongo Health Research Center 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/usnavyresearch 
Hale, Braden R.; Owusu-Agyei, Seth; Fryauff, David J.; Koram, Kwadwo A.; Adjuik, Martin; Oduro, Abraham 
R.; Prescott, W. Roy; Baird, J. Kevin; Nkrumah, Francis; Ritchie, Thomas L.; Franke, Eileen D.; Binka, Fred N.; 
Horton, John; and Hoffman, Stephen L., "A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging 
Trial of Tafenoquine for Weekly Prophylaxis against Plasmodium falciparum" (2003). U.S. Navy Research. 
81. 
https://digitalcommons.unl.edu/usnavyresearch/81 
This Article is brought to you for free and open access by the U.S. Department of Defense at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in U.S. Navy Research by an 
authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
Braden R. Hale, Seth Owusu-Agyei, David J. Fryauff, Kwadwo A. Koram, Martin Adjuik, Abraham R. Oduro, 
W. Roy Prescott, J. Kevin Baird, Francis Nkrumah, Thomas L. Ritchie, Eileen D. Franke, Fred N. Binka, John 
Horton, and Stephen L. Hoffman 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
usnavyresearch/81 
Tafenoquine Prophylaxis against Malaria • CID 2003:36 (1 March) • 541
M A J O R A R T I C L E
A Randomized, Double-Blind,
Placebo-Controlled, Dose-Ranging Trial
of Tafenoquine for Weekly Prophylaxis
against Plasmodium falciparum
Braden R. Hale,1 Seth Owusu-Agyei,2 David J. Fryauff,4 Kwadwo A. Koram,3 Martin Adjuik,2 Abraham R. Oduro,2
W. Roy Prescott,5 J. Kevin Baird,3 Francis Nkrumah,4 Thomas L. Ritchie,4 Eileen D. Franke,1 Fred N. Binka,2,6
John Horton,7 and Stephen L. Hoffman4,a
1US Navy Medical Research Unit No. 3, Cairo, Egypt; 2Navrongo Health Research Center, Navrongo, and 3Noguchi Memorial Institute of Medical
Research, Accra, Ghana; 4Naval Medical Research Center, Silver Spring, and 5US Army Medical Materiel Development Activity, Fort Detrick,
Maryland; 6World Health Organization, Geneva, Switzerland; and 7GlaxoSmithKline, Harlow, United Kingdom
Tafenoquine is a promising new 8-aminoquinoline drug that may be useful for malaria prophylaxis in non-
pregnant persons with normal glucose-6-phosphate dehydrogenase (G6PD) function. A randomized, double-
blind, placebo-controlled chemoprophylaxis trial was conducted with adult residents of northern Ghana to
determine the minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium
falciparum. The primary end point was a positive malaria blood smear result during the 13 weeks of study
drug coverage. Relative to the placebo, all 4 tafenoquine dosages demonstrated significant protection against
P. falciparum infection: for 25 mg/week, protective efficacy was 32% (95% confidence interval [CI], 20%–43%);
for 50 mg/week, 84% (95% CI, 75%–91%); for 100 mg/week, 87% (95% CI, 78%–93%); and for 200 mg/week,
86% (95% CI, 76%–92%). The mefloquine dosage of 250 mg/week also demonstrated significant protection
against P. falciparum infection (protective efficacy, 86%; 95% CI, 72%–93%). There was little difference between
study groups in the adverse events reported, and there was no evidence of a relationship between tafenoquine
dosage and reports of physical complaints or the occurrence of abnormal laboratory parameters. Tafenoquine
dosages of 50, 100, and 200 mg/week were safe, well tolerated, and effective against P. falciparum infection
in this study population.
Drugs used to prevent malarial infection and disease
face the growing threat of resistance in many parts of
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the world. The armamentarium against malaria must
be expanded to counter this threat and to provide new,
easily used, and well tolerated chemoprophylactic op-
tions to travelers and deployed military personnel. A
significant addition would be a long-acting drug that
eliminates the early, liver stages of malaria-causing spe-
cies before they mature into symptom-producing
blood-stage forms, which would allow for the early or
immediate discontinuation of the drug’s use after in-
dividuals who received the drug leave a malarious area.
Currently, the only drugs near to meeting this criterion
are primaquine and atovaquone-proguanil (Malarone;
GlaxoSmithKline). Despite impressive prophylactic ef-
ficacy against Plasmodium falciparum and Plasmodium
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vivax infection [1–5], primaquine is not yet approved for this
indication. Atovaquone-proguanil is an approved drug com-
bination with both suppressive and causal prophylactic effects
against P. falciparum infection, and limited data also show its
protective efficacy against P. vivax infection [6–9]. Atovaquone-
proguanil therapy should continue for 7 days following ex-
posure to these parasites.
Tafenoquine (formerly WR 238605) is a new primaquine an-
alogue discovered by the US Army and codeveloped by the US
Army Medical Materiel Development Activity and Glaxo-
SmithKline. Like primaquine, tafenoquine is active against Plas-
modium liver stages, gametocytes, and sporozoites [10, 11], but
unlike primaquine, tafenoquine has pronounced activity against
the blood stages, including those of multidrug-resistant malaria-
causing species [12, 13]. In addition, tafenoquine is longer-acting
and can be administered once weekly [13, 14], in contrast to the
daily regimens required for primaquine [1–5, 15] and atova-
quone-proguanil [6–8, 16]. Of note, the use of tafenoquine would
be limited to persons who are not pregnant and who have normal
glucose-6-phosphate dehydrogenase (G6PD) activity. As an 8-
aminoquinoline, tafenoquine would cause hemolysis in persons
with G6PD deficiency, and must not be used during pregnancy
because of its potential effect on the fetus [17–19]. Both pri-
maquine and tafenoquine may induce a generally mild, reversible
methemoglobinemia [1, 4, 14, 17, 18].
Tafenoquine has been evaluated in multiple human volunteer
trials and shows potent prophylactic activity against P. falci-
parum infection [20, 21]. Tafenoquine prophylaxis in Kenyans
was effective at dosages of 200 and 400 mg/week, but the lowest
effective dose of the drug has not yet been identified. The aims
of this study were to evaluate the protective efficacy, safety, and
tolerability of tafenoquine across a broad range of dosages and
to assess the relative protection afforded by mefloquine, the
current once-weekly standard used by the US military for ma-
laria prevention. Results obtained in this trial would guide dos-
age selection for phase III studies, in which the target popu-
lation of users would be largely nonimmune to malaria.
SUBJECTS, MATERIALS, AND METHODS
Study site and subjects. The Kassena-Nankana district of
northeastern Ghana was selected as the study site on the basis
of the logistic capacity and quantified malaria epidemiology of
this region. Preliminary study, there, of adults who had com-
pleted radical cure treatment had determined the 20-week cu-
mulative incidence of reinfection by P. falciparum to be nearly
100% [22].
Study design and sample size estimation. A double-blind,
placebo-controlled prospective trial was designed to evaluate the
efficacy, tolerability, and safety of 4 different weekly dosages (25,
50, 100, or 200 mg) of tafenoquine (base; GlaxoSmithKline).
Once-weekly prophylaxis with mefloquine (salt; Lariam [US for-
mulation]; Hoffmann–La Roche), 250 mg/week, served as a pos-
itive reference. A placebo (tafenoquine placebo, GlaxoSmith-
Kline; mefloquine placebo, Hoffmann-La Roche) served as the
negative comparator. On the basis of a projected 12-week attack
rate of 70% in the placebo group and an anticipated protective
efficacy (PE) of 90%–95% for the highest dosage of tafenoquine,
an enrollment of 100 subjects per study arm would provide190%
power to maintain the lower 95% confidence limit for the PE
at 175%. The size of the mefloquine group was reduced because
tafenoquine-placebo comparisons were of primary interest.
Ethical approval, subject selection, and consent. The pro-
tocol and consent forms were reviewed and approved by sci-
entific and ethical review boards of the Ghanaian Ministry of
Health, US Army, and US Navy. Traditional chiefs, community
leaders, and local residents granted local approval of this study.
Tribal language consent forms were read by or to every pro-
spective subject. Individual affirmation of informed consent
was obtained from those residents wishing to participate.
Screening. Screening was conducted over a period of 2
weeks (13–26 August 1998); informed consent and personal
details were obtained, physical examination was performed, and
15 mL of venous blood was obtained for laboratory screening.
Inclusion criteria included the following: age of 18–60 years
(men) or 50–60 years (women); lack of significant systemic
illness as determined by history, physical examination, and clin-
ical laboratory test results (including negative results of a urine
pregnancy test for women); and absence of seizures or other
neuropsychiatric illness (past or present). The high rate of preg-
nancy and breast-feeding in women aged 18–49 years precluded
their enrollment. For all subjects, the following clinical labo-
ratory tests were done: complete blood count (Coulter Counter;
Beckman-Coulter); serum biochemical analysis of levels of al-
anine aminotransferase (ALT), total bilirubin, and creatinine
(Reflotron; Boeringer-Mannheim); dipstick urinalysis; whole-
blood screening for G6PD deficiency by means of 2 separate
G6PD qualitative assays (visual fluorescence [no. 203-A] and
visual color [no. 400K]; Sigma); and microscopy of Giemsa-
stained thick and thin blood smears.
Randomization. Subjects were randomly assigned to 1 of
6 study arms. The randomization code was generated in blocks
of 11 numbers (2 numbers for each of the 4 tafenoquine groups,
2 for the placebo group, and 1 for the mefloquine group). Code
numbers were assigned according to the chronological order
of appearance of the subjects at screening. Study drugs were
prepackaged and prelabeled with a unique study number ac-
cording to the randomization code.
Drug administration. Before prophylaxis, subjects re-
ceived an oral radical cure regimen to eliminate active and latent
Plasmodium parasites. The regimen was composed of quinine
sulfate (salt; Zenith Goldline), 600 mg 3 times daily for 4 days,
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Figure 1. Design of randomized, double-blind, placebo-controlled che-
moprophylaxis trial to determine the minimum effective weekly dose of
tafenoquine for the prevention of infection by Plasmodium falciparum.
TQ, tafenoquine.
followed by a 7-day course of doxycycline (Vibramycin; Pfizer),
100 mg twice daily, and primaquine phosphate (base; Sanofi-
Winthrop), 30 mg once daily, followed by a 7-day course of
primaquine phosphate, 30 mg once daily, for a total treatment
course of 18 days. After the 18-day radical cure phase and a
5-day drug-free break (to permit recovery from primaquine-
induced methemoglobinemia), each subject received a super-
vised 3-day loading dose of the study drug or placebo which
they had been randomized to receive. The first dose of the
weekly regimen of study drug or placebo was given 7 days after
completion of the loading dose. All medications were given
after a meal and witnessed by a member of the study team. A
“double-dummy” design allowed double-blind administration
of tafenoquine and mefloquine active drugs and their corre-
sponding placebos.
Surveillance. Study subjects were visited daily in their
homes during the radical cure and loading dose phases of this
study to check the safety of and subjects’ compliance with the
drug regimens. During the prophylaxis and follow-up phases,
health workers visited the subjects 3 times weekly; 1 visit co-
incided with drug administration and blood smear preparation.
Health workers checked the subjects’ health at each visit and
reported complaints or symptoms to the study-team physicians.
Subjects with physical complaints were examined by a study
physician the next day or on an emergent basis, as needed.
Hematologic analysis was done on days 4 and 10 after starting
the loading dose phase and during weeks 4, 8, 12, and 15.
Biochemical analysis was done during weeks 4, 8, 12, and 15.
Parasitologic and clinical assessment and efficacy end
points. Thick and thin blood films were Giemsa stained and
read for the presence of malaria-causing parasites by qualified
microscopists. All slides positive for the presence of malaria-
causing parasites, and an equal number of randomly selected
slides with negative results were reevaluated by a second
(blinded) microscopist. Two hundred thick-film fields were ex-
amined at 1000 magnification before assigning a negative
result. For primary efficacy, subjects were considered to have
experienced prophylaxis failure if they had a single blood film
with a positive result at any time between the first loading dose
and 7 days after the last dose of study drug or placebo. Unless
terminated earlier, study drug or placebo administration ended
when subjects became symptomatic and had positive blood
smear results, when they had 2 consecutive positive blood smear
results, or when they completed 12 weeks of prophylaxis. Symp-
tomatic malaria was defined as a positive blood smear result
in conjunction with any 2 of the following symptoms: fever
(axillary temperature of 37.5C), chills, myalgia or arthralgia,
headache, nausea, vomiting, dizziness, or abdominal pain.
Symptomatic subjects were treated with oral chloroquine ac-
cording to the local standard of care and assessed for their
response to therapy. Subjects were monitored for an additional
4 weeks beyond the final, week 12 dose of the study drug or
placebo to assess the duration of the prophylactic effect.
Statistical analysis. Data were double-entered and veri-
fied, and data files were locked before analysis. Data analysis
for efficacy used 2 data sets: the “full, intent-to-treat” data set
( ), comprising all subjects who took at least 1 dose ofnp 509
the weekly study drug or placebo, and the “per-protocol” data
set ( ), comprising those subjects who strictly fulfillednp 428
the protocol criteria. The safety and tolerability analyses in-
cluded data for all subjects who received at least 1 dose of the
study drug or placebo ( ).np 513
Calculation of the PE for each active treatment compared
with placebo was based on the crude attack rate (defined as
the number of cases of prophylaxis failure/the number of sub-
jects), with 95% CIs derived using the method described by
Koopman [23]. Additionally, the incidence density of infection
(defined as the number of prophylaxis failures/person-years of
treatment) was calculated by life-table analysis [24]. The effects
of weight and age on prophylaxis outcome were assessed by
logistic regression, initially for individual tafenoquine groups
and then for all of the tafenoquine groups.
Conditions reported at nonroutine clinic visits and routine
home visits were summarized as the number of subjects who
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Table 1. Sex, age, and weight composition of groups in a randomized, double-blind, placebo-controlled chemoprophylaxis
trial to determine the minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium
falciparum.
Characteristic
Placebo
group
(n p 94)
Tafenoquine groups, by dosage
Mef group,
250 mg/week
(n p 46)
All groups
(n p 509)
25 mg/week
(n p 93)
50 mg/week
(n p 91)
100 mg/week
(n p 94)
200 mg/week
(n p 91)
Women, no. (%) 32 (34) 38 (41) 34 (37) 27 (29) 32 (35) 13 (28) 176 (35)
Age, years
Mean 53 53 53 53 54 52 53
Median 53 54 54 54 54 53 54
Range 46–60 45–59 38–59 46–60 46–69 45–59 38–69
Weight, kg
Mean (SD) 48.0 (6.8) 46.0 (4.6) 49.9 (7.3) 47.3 (7.1) 44.9 (4.3) 49.1 (5.0) 47.3 (6.2)
Median 47 46 50 47 45 50 47
Range 35–65 35–54 40–71 35–62 35–55 40–57 35–71
Men, no. (%) 62 (66) 55 (59) 57 (63) 67 (71) 59 (65) 33 (72) 333 (65)
Age, years
Mean 39 40 36 38 39 37 38
Median 40 40 36 38 38 35 39
Range 17–60 14–63 18–58 18–60 18–63 19–58 14–90
Weight, kg
Mean (SD) 54.8 (6.3) 56.3 (9.0) 55.4 (7.9) 55.4 (6.8) 54.1 (6.6) 56.3 (6.4) 55.3 (7.2)
Median 55 55 56 56 54 57 55
Range 35–73 37–90 33–77 36–68 36–72 42–72 33–90
NOTE. Mef, mefloquine.
reported each condition. Laboratory data were also summa-
rized. Statistical analyses of safety and laboratory data were
limited, because the study was not powered to make these
comparisons.
RESULTS
Subject population. The flow chart (figure 1) shows that 338
of the 868 candidates screened were not enrolled in the study.
G6PD deficiency accounted for 179 of 338 exclusions and was
present in 20.6% of this adult population. As a result of in-
clusion criteria limiting their enrollment, women comprised
35% of the enrollees, were older, and weighed less than did
their male counterparts (table 1). Forty-seven percent of the
screened population was parasitemic at the enrollment screen-
ing. The radical cure phase of treatment was completed by 530
subjects, and 509 went on to receive the 3-day loading dose
and first dose of the weekly regimen of the study drug or
placebo, which marked the full, intent-to-treat data set and
start of the 12-week prophylaxis period. Blood smear findings
were negative for all subjects at the start of administration of
the loading dose.
Efficacy. Outcome measurements for the incidence of P.
falciparum infection and PE of drug groups relative to the
placebo group are presented in table 2 for the full, intent-to-
treat data set. Comparable levels of protection, ranging from
84.4% to 87.2%, were demonstrated in the tafenoquine groups
receiving dosages of 50, 100, and 200 mg/week and in the
reference group receiving mefloquine, 250 mg/week. Measure-
ments of PE, based on the incidence density of infection, ranged
from 92.8% to 94.3% for these groups. The cumulative pro-
portion of subjects who remained uninfected over time is
shown by group in a Kaplan-Meier plot (figure 2). Comparable
measurements of crude incidence, incidence density, cumula-
tive incidence, and PE were obtained for both the full, in-
tent-to-treat data set ( ) and the per-protocol data setnp 509
( ) with use of the first occurrence of parasitemia asnp 428
the primary outcome variable. Mild malaria symptoms co-
incident with parasitemia were reported in the placebo group
(11 of 86 subjects) and in the groups receiving tafenoquine
dosages of 25 mg/week (5 of 58), 50 mg/week (1 of 13), and
200 mg/week (1 of 12). Follow-up after chloroquine therapy
revealed no cases of treatment failure.
Continued weekly administration of the study drug or pla-
cebo after the first positive blood smear result for asymptomatic
subjects revealed that the tafenoquine regimens of 100 and 200
mg/week suppressed any further reappearance of parasites dur-
ing the remaining period of prophylaxis. Monitoring of subjects
4 weeks beyond the week 12 prophylaxis end point showed
new and recurrent cases of parasitemia in the groups receiving
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Figure 2. Cumulative proportions of subjects in the study groups who remained malaria-free. The days at risk comprised the time between the
first loading dose and 7 days after the last dose of study drug or placebo. MF, mefloquine; TQ, tafenoquine; wk, week.
Figure 3. Mean alanine aminotransferase (ALT) profiles over time for the study groups. TQ, tafenoquine; wk, week.
tafenoquine dosages of 25 mg/week (4 new and 12 recurrent
cases of parasitemia) or 50 mg/week (7 new and 1 recurrent
case), or mefloquine dosages of 250 mg/week (1 new and 2
recurrent cases), but no new infections were seen in the groups
receiving tafenoquine dosages of 100 or 200 mg/week.
The analysis of dose response (in the tafenoquine arms only)
indicated a significant interaction between treatment efficacy
and body weight ( ), primarily because of a higher in-P ! .001
cidence of positive blood smear results among heavier subjects
in the tafenoquine group receiving the lowest dosage (25 mg/
week). Relative to the placebo cohorts, the PE in the group
receiving tafenoquine, 25 mg/week, for those with a body
weight lower than median was 56%, compared with a PE of
7% for those with a weight greater than the median.
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Table 2. Primary outcomes in randomized, double-blind, placebo-controlled chemoprophylaxis trial to determine the
minimum effective weekly dose of tafenoquine for the prevention of infection by Plasmodium falciparum: incidence of
infection and protective efficacy of study drug regimens relative to placebo.
Variable
Placebo
group
(n p 94)
Tafenoquine groups, by dosage
Mef group,
250 mg/week
(n p 46)
25 mg/week
(n p 93)
50 mg/week
(n p 91)
100 mg/week
(n p 94)
200 mg/week
(n p 91)
Positive blood-smear result,
no. of subjects 86 58 13 11 12 6
Incidence (attack rate), % 91.5 62.4 14.3 11.7 13.2 13.0
Protective efficacy, % NA 31.8a 84.4a 87.2a 85.6a 85.7a
Lower 95% confidence limit NA 20.2 74.8 78.3 76.2 71.9
Upper 95% confidence limit NA 43.4 90.7 92.7 91.6 93.3
Total person-weeksb 504 799 1079 1148 1110 564
Incidence density per
subject-year 8.9 3.8 0.6 0.5 0.6 0.6
NOTE. Protective efficacy , where of subjects with prophylaxis failure in the placebo(%)p {[I  I ]/I }100 I p numberplacebo drug placebo placebo
of subjects at risk in the placebo group, and of subjects with prophylaxis failure in the drug of subjectsgroup/number I p number group/numberdrug
at risk in the drug group. Mef, mefloquine; NA, not applicable.
a Significantly different ( ) from the value for placebo group.P ! .05
b Person-time from the start of the loading dose to 7 days after the final administration of study drug or placebo or the time of discontinuation
from the study.
Table 3. Adverse events among subjects during the period of study drug or placebo administration.
Variable
Placebo
group
Tafenoquine groups, by dosage
Mef group,
250 mg/week25 mg/week 50 mg/week 100 mg/week 200 mg/week
No. of subjects (safety population) 94 93 93 94 93 46
No. (%) of subjects with AEs
at clinic presentation 52 (55) 47 (50) 50 (54) 59 (63) 53 (57) 21 (46)
No. of clinic visits 74 74 85 100 91 29
Total no. of AEs reported
at clinic visits 91 92 107 129 102 34
No. (%) of subjects who
reported AEs from home 60 (64) 60 (64) 58 (62) 62 (66) 54 (58) 25 (54)
Total no. of home visits
at which AEs were reported 102 109 112 119 90 41
NOTE. AE, adverse event; Mef, mefloquine.
Tolerability. Table 3 summarizes adverse events in the
study groups during drug or placebo administration, which are
separated into those reported by subjects during visits to the
health clinic and those reported by subjects during home-visits
by study personnel. The tafenoquine groups demonstrated ad-
verse-event rates comparable to those of the placebo group and
showed no evidence of a dose-related effect; rates of clinic or
home visits and of enumerated adverse events were comparable
among the 4 tafenoquine groups. Physical complaints involving
the musculoskeletal, gastrointestinal, and respiratory systems
collectively accounted for 52%–70% of the total adverse events
that prompted health clinic visits in each group (table 4). There
were 9 serious adverse events in the study. Six of these occurred
during the period of study drug or placebo administration,
only 1 of which resulted in premature discontinuation of ther-
apy. No serious adverse events were considered by study phy-
sicians to be related to the study drug, and no deaths occurred.
Safety. Thirty-three abnormal clinical laboratory test re-
sults were considered possibly or probably related to the study
drug and led to the premature discontinuation of treatment
for these subjects. Among these were 23 cases of abnormally
elevated ALT levels, ranging from 61.9 to 193 U/L (placebo
group, 2 cases; tafenoquine, 25 mg/week, 4 cases; tafenoquine,
50 mg/week, 4 cases; tafenoquine, 100 mg/week, 7 cases; and
tafenoquine, 200 mg/week, 6 cases), 8 cases of low hemoglobin
levels, !8.0 g/dL (placebo group, 1 case; tafenoquine, 25 mg/
week, 2 cases; tafenoquine, 50 mg/week, 2 cases; and tafeno-
quine, 200 mg/week, 3 cases), and 2 cases of thrombocytopenia,
which were subsequently found to be spurious and due to
platelet clumping. The majority of abnormal ALT values were
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Table 4. Adverse events that occurred at a frequency of 15.0% in each study group.
Adverse event
Placebo
group
(n p 94)
Tafenoquine groups, by dosage
Mef group,
250 mg/week
(n p 46)
25 mg/week
(n p 93)
50 mg/week
(n p 93)
100 mg/week
(n p 94)
200 mg/week
(n p 93)
Dysentery/diarrhea 15 (17.0) 14 (16.9) 14 (13.5) 20 (17.5) 12 (12.4) 4 (12.5)
Abdominal pain 6 (6.8) 3 (3.6) 3 (2.9) 9 (7.9) 2 (2.1) 3 (9.4)
Gastritis 2 (2.3) 2 (2.4) 1 (1.0) 2 (1.7) 5 (5.1) 1 (3.1)
Back pain 10 (11.4) 5 (6.0) 4 (3.8) 6 (5.3) 6 (6.2) 0
Myalgia 4 (4.5) 9 (10.8) 5 (4.8) 12 (10.5) 13 (13.4) 3 (9.4)
Polyarthralgia/arthralgia 3 (3.4) 4 (4.8) 9 (8.6) 7 (6.1) 5 (5.1) 0
Respiratory tract infection 7 (7.9) 9 (10.8) 14 (13.5) 18 (15.8) 14 (14.4) 9 (28.1)
Sore throat 6 (6.8) 3 (3.6) 7 (6.7) 6 (5.3) 4 (4.1) 1 (3.1)
Rash 7 (7.9) 0 2 (1.9) 3 (2.6) 1 (1.0) 1 (3.1)
Headache 6 (6.8) 5 (6.0) 7 (6.7) 15 (13.2) 4 (4.1) 1 (3.1)
Clinical malaria 4 (4.5) 7 (8.4) 0 0 4 (4.1) 0
Other 18 (20.4) 22 (26.5) 38 (36.5) 16 (14.0) 27 (27.8) 9 (28.1)
11 88 83 104 114 97 32
NOTE. Data are no. (%) of subjects unless otherwise indicated. Mef, mefloquine.
detected at the routine week 4 blood test (18 cases of abnormal
ALT values in week 4, 3 cases in week 8, and 2 cases in week
15). Nearly every subject, irrespective of study arm, experienced
a notable, predominantly mild elevation in ALT level from base-
line to week 4 that progressively diminished through the period
of weekly study drug or placebo administration to the end point
(figure 3). There were no dose-related differences between taf-
enoquine groups in either the frequency or magnitude of el-
evated ALT values. No association was observed between ALT
levels and weight cohorts in either of the high-dosage tafeno-
quine groups. Subjects with abnormally elevated ALT levels
improved and/or their ALT levels normalized after cessation of
tafenoquine therapy.
Hematologic profiles for the 6 study arms followed virtually
identical trends over the 6 time points at which samples were
obtained. In each arm, the radical cure phase, from baseline
(4 weeks) to the start of study drug or placebo administration
(time 0), was characterized by generally minor elevations in
hemoglobin levels, minor increases in leukocyte counts, and
minor decreases in platelet counts. During the period from the
initiation of the loading-dose phase through the 12-week course
of weekly prophylaxis, these levels demonstrated recovery to-
ward mean baseline values for all subject groups.
DISCUSSION
The purpose of this trial was to study the dose-related protective
efficacy, tolerability, and safety of 4 different weekly dosing
regimens of tafenoquine, ranging from 25 to 200 mg/week. The
trial was designed to permit analysis of the relationship between
tafenoquine dosage and PE, relative to placebo, but the trial
was not powered to allow for more than a descriptive com-
parison of the efficacy and safety of the tafenoquine dosages,
relative to the mefloquine dosage. This trial was the next logical
step from the recent phase II trials in Africa of tafenoquine
prophylaxis with dosages of 200 mg/week and 400 mg/week
[20] and with a 400-mg daily, 3-day loading-dose-only regimen
[20, 21]. As is the case with other 8-aminoquinoline com-
pounds, administration of tafenoquine to G6PD-deficient per-
sons runs the risk of inducing the significant side effect of
intravascular hemolysis [13, 14, 18, 21]. Careful preliminary
screening of subjects for G6PD deficiency and confirmatory
retesting was necessary to ensure the safe conduct of our trial.
Despite the range of lower concentrations studied, we saw
no dose-dependent continuum in our results. We found com-
parably high levels of efficacy and comparably infrequent re-
ports of adverse events for the tafenoquine dosages of 50, 100,
and 200 mg/week. Similar PEs and CIs were calculated in a 13-
week trial of tafenoquine in which Kenyan adults received dos-
ages of 200 mg/week [21]. However, in contrast to the gastro-
intestinal and dermatologic complaints associated with the 200
and 400 mg/week tafenoquine dosage regimens in Kenyans
[21], no clear adverse event trends were seen in our Ghanaian
treatment groups.
Intermediate protection (PE, 32%) significantly greater than
that afforded by placebo but less than that afforded by tafeno-
quine, 50 mg/week, was observed in the arm receiving tafen-
oquine, 25 mg/week. Within-group cohort comparison based
on division of the group receiving tafenoquine, 25 mg/week,
at the group’s median body weight (51 kg) showed that this
lowest tafenoquine dosage offered significantly better protec-
tion to subjects who weighed !51 kg (PE, 56%; 95% CI,
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37%–69%), whereas those who weighed 151 kg derived no
better protection (PE, 7%; 95% CI, 9% to 21%) than did
subjects who received placebo.
Laboratory test results yielded no indication of dose-related
or cumulative toxicity associated with tafenoquine loading
doses and weekly prophylaxis. Of note, early changes from
baseline (elevated hemoglobin levels, WBC counts, and ALT
levels, and decreased platelet counts and bilirubin levels) were
seen in the placebo, tafenoquine, and mefloquine study arms;
these changes were possibly a result of the radical cure regimen.
Elevations in hemoglobin levels and leukocyte counts may re-
flect a reversal of malaria’s effects on bone marrow and eryth-
ropoiesis [25–27] and/or drug-induced stimulation or distur-
bance [17, 28].
Abnormal elevation of the ALT level to 160 U/L was the
main reason for the premature discontinuation of treatment
for subjects in our study and was an effect largely confined to
the tafenoquine groups. No abnormal ALT findings were re-
ported in 4 previous trials in humans, 3 of which administered
tafenoquine at higher doses and at more frequent (daily) in-
tervals [14, 20, 21, 29].
In summary, this large trial demonstrates the minimum ef-
fective weekly dose of tafenoquine in semi-immune subjects
and provides key information about dosage selection for phase
III studies, in which the target population for the ultimate use
of the drug would be largely nonimmune. Tafenoquine has the
potential to be used in a variety of situations beyond that of
chemoprophylaxis. The compound is effective as part of a rad-
ical cure regimen for P. vivax infection [29]. There could be a
role for this drug in outbreak management and long-term ma-
laria suppression because of its extended half-life and potential
transmission-blocking qualities [10, 13]. In any of these roles,
sensitive screening for G6PD deficiency and for pregnancy are
required to ensure the safe use of this potent and promising
new antimalarial drug.
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